Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
ESSA Pharma Inc. (Nasdaq: EPIX) announced a public offering of 4,830,918 common shares priced at $27.00 per share, totaling approximately $130.4 million. The underwriters have a 30-day option to purchase an additional 724,637 shares. After expenses, the net proceeds are expected to be around $121.6 million, aimed at funding pre-clinical and clinical activities, R&D, as well as general corporate purposes. The offering is set to close around February 22, 2021.
ESSA Pharma Inc. (Nasdaq: EPIX) has initiated a public offering to sell up to $100 million of its common shares. The proceeds will support clinical and pre-clinical activities, along with R&D, manufacturing, and general corporate needs. The offering includes a potential 30-day option for underwriters to acquire an additional 15% of the shares. Jefferies and Piper Sandler lead the offering, which is contingent on market conditions. The shares will be made available under an effective shelf registration statement filed with the SEC.
ESSA Pharma Inc. (NASDAQ: EPIX) presented promising preclinical and clinical data for EPI-7386 at the 2021 ASCO GU Cancers Symposium, relating to its Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC). EPI-7386 was well-tolerated in the initial 200 mg cohort with no serious adverse events. Notably, one patient showed over a 50% decline in prostate-specific antigen (PSA) levels after 12 weeks. The company plans further evaluation at higher doses, with more data anticipated in the second half of 2021.
ESSA Pharma Inc. (NASDAQ: EPIX) announced financial results for Q1 2021, reporting a net loss of $6.5 million ($0.20 loss per share) and increased R&D expenses of $4.5 million due to the Phase 1 trial of EPI-7386. The company raised $48.9 million in a public offering and received FDA Fast Track Designation for EPI-7386. A collaboration with Janssen Research will evaluate EPI-7386 with existing therapies for metastatic castration-resistant prostate cancer. ESSA's cash reserves stood at $74.5 million as of December 31, 2020.
ESSA Pharma Inc. (Nasdaq: EPIX) announced a collaboration with Janssen Research & Development to evaluate its androgen receptor inhibitor, EPI-7386, in combination with apalutamide and abiraterone acetate for metastatic castration-resistant prostate cancer (mCRPC) patients. Janssen will sponsor two Phase 1/2 studies, covering all associated costs except EPI-7386's manufacturing expenses. The trials are set to start in 2021, and ESSA retains all rights to EPI-7386. EPI-7386 has received Fast Track designation from the FDA for mCRPC treatment.
ESSA Pharma Inc. (NASDAQ: EPIX) reported a net loss of $23.4 million for the fiscal year ending September 30, 2020, compared to $12.8 million in the previous year. The increase in loss is attributed to rising Research and Development (R&D) expenditures, which reached $12.1 million, and General and Administration (G&A) expenses of $11.4 million. The company received FDA Fast Track Designation for its drug EPI-7386 and raised $48.9 million in a public offering to support its clinical studies. As of September 30, 2020, ESSA had cash reserves of $78.3 million.
ESSA Pharma Inc. (Nasdaq: EPIX) announced its participation in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, where CEO Dr. David R. Parkinson will present a corporate overview. One-on-one meetings with executives will be available from December 1-3, 2020. The presentation will be accessible via live webcast on the company's Investor Relations page, and a replay will be available for 90 days. ESSA focuses on developing novel therapies for castration-resistant prostate cancer, with recent regulatory approvals for its drug EPI-7386.
ESSA Pharma Inc. (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on prostate cancer therapies, will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:00 AM PT, and at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 10:45 AM PT. CEO Dr. David R. Parkinson will provide a corporate overview. One-on-one meetings will be available from November 16-19. Presentations will be webcast live, with replays accessible for 90 days on www.essapharma.com.
ESSA Pharma Inc. (NASDAQ: EPIX) announced its intention to voluntarily delist its common shares from the TSX Venture Exchange, effective around October 30, 2020. This decision is based on an evaluation revealing that most trading occurs on the NASDAQ, and aims to enhance liquidity, reduce costs, and optimize regulatory compliance. The delisting will not impact the company's NASDAQ listing. ESSA focuses on developing novel therapies for prostate cancer, specifically for patients with advanced disease.
ESSA Pharma Inc. (Nasdaq: EPIX) presented new preclinical data on EPI-7386, an androgen receptor inhibitor, at the 32nd EORTC-NCI-AACR Symposium. The findings show EPI-7386's interaction with both full-length and splice variant androgen receptors, indicating its superior effectiveness compared to enzalutamide in specific prostate cancer cell models. These insights strengthen the rationale for further studies of EPI-7386 in patients with prostate cancer resistant to current therapies. The company is conducting a Phase 1 study of EPI-7386 in metastatic castration-resistant prostate cancer.
